PLEASE NOTE: THIS ACTIVITY IS NO LONGER AVAILABLE FOR CME CREDIT
Conference Overview and Format
Target Audience
Commercial Support Acknowledgement
Learning Objectives
Conference Chairpersons
Faculty
Program Agenda (Interactive)
Accreditation Statement/Credit Designation Statement
Disclosure of Conflict of Interest
CME Credit Instructions
Cultural and Linguistic Competency
This online review of the The First Annual Combination and Novel HCV Therapies Conference (CONO 2011), held from July 22-23, 2011 in New York City, offers viewer participants a unique opportunity to stay current with important research regarding the treatment of HCV infection and the developing therapies and therapeutic strategies that have the potential to become the future standard of care. Participants will be able to view the presentations and panel discussions as they occurred during the live conference of which provided the latest information on new findings that are transforming the treatment of this serious infection and offering patients and clinicians the means to significantly reduce morbidity and mortality and improve cure rates. CONO 2011 featured prominent clinicians and researchers in the field of HCV treatment who will shared their insights into exciting developments in this rapidly changing clinical field and we are excited about the opportunity to bring the conference to you online. There are no prerequisites and no registration fees.
This activity has been designed to meet the educational needs of physicians, physician assistants, nurse practitioners and other health care providers who diagnose and manage patients with hepatitis C. There are no prerequisites and no registration fees.
This activity is supported by an educational grant from Kadmon Pharmaceuticals in accordance with ACCME accreditation Standards for Commercial Support.
Upon completion of the program, participants should be able to:
Discuss and apply in clinical practice clinical research studies comparing various CHC therapy regimens and strategies;
Utilize evidence-based methods to improve outcomes with CHC therapy and manage anti-HCV drug adverse effects;
Develop an appropriate, individualized treatment regimen for CHC by gathering information from the patient, including past treatment history, which maximizes the chance of treatment success;
Summarize the studies of new and developing CHC therapies and select the appropriate therapeutic choices and timing in CHC patients;
Diagnose and optimally manage patients with CHC.
Release Date: September 9, 2011
Expiration Date: September 9, 2012
PLEASE NOTE: THIS ACTIVITY IS NO LONGER AVAILABLE FOR CME CREDIT
Estimated time to complete the CONO 2011 Online Program: 13.25 hours (partial credit is allowed)
Media: Internet
|
Douglas T. Dieterich, MD Professor of Medicine Director of Outpatient Hepatology, Division of Liver Diseases Director of CME, Department of Medicine, Mount Sinai School of Medicine New York, New York |
| Paul J. Pockros, MD Head, Division of Gastroenterology/Hepatology Director, SC Liver Research Consortium The Scripps Clinic La Jolla, California |
| Mark Sulkowski, MD Associate Professor of Medicine and Medical Director, Viral Hepatitis Center, Johns Hopkins University School of Medicine Baltimore, Maryland |
|
Nezam H. Afdhal, MD Associate Professor of Medicine, Harvard School of Medicine Chief of Hepatology, Director of Liver Center, Beth Israel Deaconess Medical Center Boston, Massachusetts |
Michael P. Manns, MD Professor and Chairman Department of Gastroenterology, Hepatology and Endocrinology Medical School of Hannover Hannover, Germany |
K. Rajender Reddy, MD Professor of Medicine, Director of Hepatology, Medical Director of Liver Transplantation, Hospital of the University of Pennsylvania (HUP) Philadelphia, Pennsylvania |
|
Bruce R. Bacon, MD James F. King, MD Endowed Chair in Gastroenterology, Professor of Internal Medicine, Saint Louis University School of Medicine St. Louis, Missouri |
David R Nelson, MD Professor of Medicine Associate Dean, Clinical Research Director, Clinical and Translational Science Institute University of Florida Gainesville, Florida |
Kenneth E. Sherman, MD, PhD Gould Professor of MedicineDirector, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio |
|
Edwin DeJesus, MD Medical Director,Orlando Immunology Center Orlando, Florida |
Fred Poordad, MD Chief of Hepatology and Liver Transplantation, Cedars-Sinai Medical Center Associate Professor, David Geffen School of Medicine University of California, Los Angeles Los Angeles, California |
Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center Division of Gastroenterology University of California San Francisco San Francisco, California |
|
Ira Jacobson, MD Chief of Gastroenterology, Vincent Astor Professor of Clinical Medicine, Weill Medical College of Cornell University New York, New York |
Joshua D. Rabinowitz, MD, PhD |
John W. Ward, MD Director, Division of Viral HepatitisNational Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease Control and Prevention Atlanta, Georgia |
|
Teresa Wright, MD Franchise Head, Hepatitis and Hepatology Genentech South San Francisco, California |
David Bernstein, MD Chief of Gastroenterology, Hepatology and Nutrition North Shore University Hospital (NSUH) and LIJ Medical Center Manhasset, New York |
|
Session 1 - Setting the Stage
Session 2 - HCV Protease Inhibitors
Session 3 - Case Studies (K. Rajender Reddy, MD)
Session 4 - Metabolomics of Virus Infections (Joshua Rabinowitz, MD)
Session 5 – Newer Drugs in Development
Session 6 – Special Populations Session 7 – Industry/FDA Session 8 – Case Studies (Douglas Dieterich, MD) |
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Scripps Health and ViralEd, Inc.. Scripps Health is accredited by the ACCME to provide continuing medical education for physicians.
Scripps Health designates this enduring activity for a maximum of 13.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Employees of a commercial interest with business lines or products relating to the content of the CME activity will not participate in the planning or any accredited portion of the conference.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|
Nezam H. Afdhal, MD |
|
Bruce R. Bacon, MD |
|
David Bernstein, MD |
|
Edwin DeJesus, MD |
|
Douglas T. Dieterich, MD |
|
Ira Jacobson, MD |
|
Michael P. Manns, MD |
|
David R. Nelson, MD |
|
Paul Pockros, MD |
|
Fred Poordad, MD |
|
Joshua D. Rabinowitz, MD, PhD |
|
K. Rajender Reddy, MD |
|
Kenneth E. Sherman, MD, PhD |
|
Mark Sulkowski, MD |
| Norah Terrault, MD Contracted Research: Roche/Genentech; Vertex; Gilead; Novartis; Bristol-Myers Squibb Consulting Fees: Roche/Genentech; Merck; Siemens Diagnostics |
|
John W. Ward, MD |
There are no fees for participating and receiving credit for this enduring activity. During the period, September 9, 2011 through September 9, 2012 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test. Once you complete the post-test it will be automatically submitted for review.
If you successfully complete the post-test (score of 80% or higher). your certificate will be emailed to your preferred email address. If you received a score of 79% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.
PLEASE CLICK HERE to begin the CME Post-test.
This activity is in compliance with California Assembly Bill 1195 which requires that all CME activities comprising a patient care element include curriculum addressing the topic of cultural and linguistic competency. The intent of this bill is to ensure that health care professionals are able to meet the cultural and linguistic concerns of a diverse patient population through effective and appropriate professional development. Cultural and linguistic competency was incorporated into the planning of this activity. Please click HERE to view the cultural and linguistic competency resource guide.
You may contact ViralEd by phone at 1-856-506-5790 or by email at admin@viraled.com for additional assistance.
 |
 |
